Literature DB >> 19366852

Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome.

Umer Saleem1, Mahyar Khaleghi, Nils G Morgenthaler, Andreas Bergmann, Joachim Struck, Thomas H Mosley, Iftikhar J Kullo.   

Abstract

CONTEXT: Stress-mediated hypothalamic-pituitary-adrenal axis activation, regulated by arginine vasopressin (AVP), may have a role in the pathophysiology of metabolic syndrome (MetSyn).
OBJECTIVE: The objective of the study was to investigate whether plasma C-terminal provasopressin fragment (copeptin), a surrogate for circulating AVP, was associated with measures of insulin resistance and presence of MetSyn. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, community-based study, investigating novel biomarkers for vascular disease. Participants included 1293 African-Americans (AA) (64 +/- 9 yr) and 1197 non-Hispanic whites (NHW) (59 +/- 10 yr) belonging to hypertensive sibships. MAIN OUTCOME MEASURES: Plasma copeptin levels were measured by an immunoluminometric assay. MetSyn was defined per Adult Treatment Panel III criteria. Generalized estimating equations were used to assess whether plasma copeptin was associated with measures of insulin resistance and MetSyn.
RESULTS: The prevalence of MetSyn was 50% in AA and 49% in NHW. In each group, after adjustment for age and sex, plasma copeptin levels significantly correlated with body mass index, fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and (inversely) high-density lipoprotein cholesterol (P < 0.05 for each variable). In multivariable logistic regression models that adjusted for age, sex, smoking, statin use, serum creatinine, education, physical activity, and diuretic use, plasma copeptin levels in the highest quartile were associated with an increased odds ratio of having MetSyn compared with bottom quartile: odds ratio (95% confidence interval) in AA, 2.07 (1.45-2.95); in NHW, 1.74 (1.21-2.5).
CONCLUSIONS: Our findings indicate a novel cross-sectional association between plasma copeptin and measures of insulin resistance and MetSyn.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366852      PMCID: PMC2708945          DOI: 10.1210/jc.2008-2278

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  The HPA axis response to stress in women: effects of aging and fitness.

Authors:  Tinna Traustadóttir; Pamela R Bosch; Kathleen S Matt
Journal:  Psychoneuroendocrinology       Date:  2005-01-11       Impact factor: 4.905

Review 2.  The metabolic syndrome.

Authors:  Marc-Andre Cornier; Dana Dabelea; Teri L Hernandez; Rachel C Lindstrom; Amy J Steig; Nicole R Stob; Rachael E Van Pelt; Hong Wang; Robert H Eckel
Journal:  Endocr Rev       Date:  2008-10-29       Impact factor: 19.871

3.  Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis.

Authors:  Thais de A Coutinho; Stephen T Turner; Patricia A Peyser; Lawrence F Bielak; Patrick F Sheedy; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2007-01       Impact factor: 2.689

4.  Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage.

Authors:  Christina Daousi; Andrew J Dunn; Patrick M Foy; Ian A MacFarlane; Jonathan H Pinkney
Journal:  Am J Med       Date:  2005-01       Impact factor: 4.965

5.  Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals.

Authors:  Thomas J Wang; Martin G Larson; Michelle J Keyes; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Circulation       Date:  2007-03-05       Impact factor: 29.690

6.  Copeptin: clinical use of a new biomarker.

Authors:  Nils G Morgenthaler; Joachim Struck; Stefan Jochberger; Martin W Dünser
Journal:  Trends Endocrinol Metab       Date:  2008-03       Impact factor: 12.015

7.  Arginine-vasopressin mediates central and peripheral glucose regulation in response to carotid body receptor stimulation with Na-cyanide.

Authors:  Sergio Montero; Herón Mendoza; Victoria Valles; Mónica Lemus; Ramón Alvarez-Buylla; Elena R de Alvarez-Buylla
Journal:  J Appl Physiol (1985)       Date:  2006-02-23

Review 8.  Metabolic syndrome pandemic.

Authors:  Scott M Grundy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-03       Impact factor: 8.311

9.  Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.

Authors:  Gabor Szinnai; Nils G Morgenthaler; Kaspar Berneis; Joachim Struck; Beat Müller; Ulrich Keller; Mirjam Christ-Crain
Journal:  J Clin Endocrinol Metab       Date:  2007-07-17       Impact factor: 5.958

10.  C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.

Authors:  Sohail Q Khan; Onkar S Dhillon; Russell J O'Brien; Joachim Struck; Paulene A Quinn; Nils G Morgenthaler; Iain B Squire; Joan E Davies; Andreas Bergmann; Leong L Ng
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

View more
  52 in total

1.  Plasma copeptin and the risk of diabetes mellitus.

Authors:  Sofia Enhörning; Thomas J Wang; Peter M Nilsson; Peter Almgren; Bo Hedblad; Göran Berglund; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Eero Lindholm; Leif Groop; Valeria Lyssenko; Marju Orho-Melander; Christopher Newton-Cheh; Olle Melander
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

2.  Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors.

Authors:  Richard J Johnson; Peter Stenvinkel; Thomas Jensen; Miguel A Lanaspa; Carlos Roncal; Zhilin Song; Lise Bankir; Laura G Sánchez-Lozada
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

3.  Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats.

Authors:  Christopher Taveau; Catherine Chollet; Ludovic Waeckel; Dorinne Desposito; Daniel G Bichet; Marie-Françoise Arthus; Christophe Magnan; Erwann Philippe; Valerie Paradis; Fabienne Foufelle; Isabelle Hainault; Sofia Enhorning; Gilberto Velho; Ronan Roussel; Lise Bankir; Olle Melander; Nadine Bouby
Journal:  Diabetologia       Date:  2015-01-27       Impact factor: 10.122

Review 4.  Neuroendocrine drivers of risk and resilience: The influence of metabolism & mitochondria.

Authors:  Susie Turkson; Alix Kloster; Peter J Hamilton; Gretchen N Neigh
Journal:  Front Neuroendocrinol       Date:  2019-07-06       Impact factor: 8.606

5.  Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study.

Authors:  S Canivell; M Mohaupt; D Ackermann; M Pruijm; I Guessous; G Ehret; G Escher; A Pechère-Bertschi; B Vogt; O Devuyst; M Burnier; P-Y Martin; B Ponte; M Bochud
Journal:  J Endocrinol Invest       Date:  2017-12-12       Impact factor: 4.256

Review 6.  Water intake keeps type 2 diabetes away? Focus on copeptin.

Authors:  Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

7.  Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.

Authors:  Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  JCI Insight       Date:  2018-10-04

8.  Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.

Authors:  Linda G Mellbin; Lars Rydén; Kerstin Brismar; Nils G Morgenthaler; John Ohrvik; Sergiu B Catrina
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

9.  Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.

Authors:  Minako Yamaoka-Tojo; Taiki Tojo; Naonobu Takahira; Atsuhiko Matsunaga; Naoyoshi Aoyama; Takashi Masuda; Tohru Izumi
Journal:  Cardiovasc Diabetol       Date:  2010-05-14       Impact factor: 9.951

Review 10.  The brain renin-angiotensin system and cardiovascular responses to stress: insights from transgenic rats with low brain angiotensinogen.

Authors:  Amy C Arnold; Atsushi Sakima; Sherry O Kasper; Sherry Vinsant; Maria Antonia Garcia-Espinosa; Debra I Diz
Journal:  J Appl Physiol (1985)       Date:  2012-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.